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ABSTRACT
The success rate of antiretroviral therapy (ART) depends on the efficacy of the drug and 
the immune system’s ability to control virus replication. Viral load (VL) examination is a 
standard test for ART monitoring. Unfortunately, this test is still very limited, especially in 
Indonesia. CD38 expression has been studied as a predictor for disease progression and 
decreases once ART is initiated. The aim of this study was to evaluate the possible usage 
of declining CD8/38 T-cell percentages in predicting the VL. Forty-five subjects naïve 
to ART were evaluated in this observational analytic study with a prospective design. 
Data collected included the medical history, physical examination, WHO clinical staging, 
complete blood counts, CD4 cell count, and plasma VL. These data then reevaluated six 
months after ART initiation. A paired t-test, and correlation test were used to analyze 
the data. Significant differences were found in all of the laboratory parameters between 
pre and post ART. There was a weak significant positive correlation between declining 
CD8/38 T-cell percentages and declining VL after 6 months of ART (r=0.33; p=0.026), 
with r2 = 0.11. Therefore despite the linear relationship, CD38 has limited value for 
prediction of VL.
ABSTRAK
Keberhasilan antiretroviral therapy (ART) tidak hanya tergantung pada efikasi obat dalam 
menurunkan viral load (VL) tetapi juga kemampuan sistem imun dalam mengontrol 
virus. Pemeriksaan VL merupakan pemeriksaan standar dalam pemantauan ART, namun 
ketersediaan pemeriksaan tersebut masih sangat terbatas khususnya di Indonesia. Ekspresi 
CD38 telah banyak diteliti sebagai prediktor perburukan penyakit dan akan menurun 
dengan inisiasi ART. Penelitian ini bertujuan untuk mengkaji kemungkinan penggunaan 
penurunan persentase sel T CD8/38 dalam memprediksi penurunan VL. Empat puluh 
lima subyek penelitian yang belum pernah mendapat ART dievaluasi dalam penelitian 
observasional analitik dengan desain prospektif ini. Data  riwayat penyakit, pemeriksaan 
fisik, stadium klinis menurut WHO, hematologi rutin, CD4, dan VL dikumpulkan. Data 
ini kemudian dievaluasi ulang enam bulan pasca inisiasi ART. Uji t berpasangan dan uji 
korelasi digunakan untuk menganalisis data. Terdapat korelasi positif lemah bermakna 
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antara penurunan persentase sel T CD8/38 dan penurunan VL (r=0,33; p=0,0256) 
dengan r2=0,11. Meskipun terdapat hubungan yang linear, kemampuan CD8/38 dalam 
memprediksi VL masih lemah.
Keywords: Viral load - immune activation - CD8/38 T cells – ART - HIV
INTRODUCTION
Human Immunodeficiency virus (HIV) 
infection is still a global health problem. Since 
the first acquired immune deficiency syndrome 
(AIDS) case was found in 1981 and HIV was 
identified in 1983, HIV/AIDS has become 
an epidemic around the world. According 
to the AIDS epidemic report, the number of 
people living with HIV/AIDS (PLHIV) in 
the world reached 36.9 million (34.3-41.4 
million) in 2014, including 34.3 million adult 
PLHIV cases. Access to antiretroviral therapy 
(ART) has increased, with 12.9 million people 
receiving ART globally in 2013. Among 
them, 11.7 million people were from poor in 
developing countries. This group represented 
34-38% of the 32.6 million (30.8-34.7 
million) PLHIV cases that are living in poor 
in developing countries.1,2 Until September 
2014, the cumulative cases of HIV/AIDS in 
Indonesia were 206,095, and 9,796 of them 
died. In January- September 2014, 24,645 
new HIV/AIDS cases were reported. The 
Special Province of Yogyakarta represents the 
8th province with the highest AIDS prevalence 
in Indonesia; there are 26.49 cases reported 
per 100,000 people.3
Antiretroviral therapy access is increasing; 
therefore, achieving a balance between the 
cost and quality of care has been a common 
discussion topic in developing countries.4 
In developing countries with a high HIV 
infection prevalence similar to Indonesia, the 
highly active antiretroviral therapy (HAART) 
program has already been commenced and is 
administering generic drugs to reduce costs. 
Therefore, one question is, “Can laboratory 
services provide vital clinical information 
about the efficacy of HAART and patient’s 
compliance towards therapeutic protocols?” 
Another question is, “How much will it cost 
to obtain this information?”5reliable, and 
simplified flow cytometric method on single 
platform with 2-color (CD45+, CD4+ In 
developed countries, CD4 and viral load (VL) 
have been the practical standard to monitor 
patients undergoing ART; unfortunately, 
this exam is costly and requires competent 
human resources with a complete laboratory 
facility.6 In developing countries, a simple 
and affordable alternative biological marker is 
needed to improve the quality of clinical care 
for HIV infected patients.
One of the main mechanisms of HIV 
infection is the activation of the chronic 
immune response, which makes immune 
activation markers important for diagnosis and 
monitoring disease progression. It was shown 
that the activation of cellular immunity can be 
an indicator substitute for VL. This method is 
recommended because it is more affordable 
during treatment in areas with limited 
resources. Therefore, when facilities for the 
VL exam do not exist, the level of activated 
CD8 T cells can be used to complement and 
improve the prognostic value of CD4 T cell 
counts in monitoring ART. Examining CD4 
and activated CD8 T cells uses the same 
EDTA blood samples and flowcytometry. 
Therefore, using CD8/38 T cell percentages 
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can contribute to cost reductions when 
monitoring HAART.6 
The aim of this study was to identify 
the possible usage of declining CD8/38 
T-cell percentages as a marker of predicting 
declining VL in patients recently diagnosed 
with HIV 6 months post HAART.
MATERIALS AND METHODS
Subjects
Eighty newly infected HIV patients 
were recruited for an observational study 
performed at the Edelweiss Policlinic at Dr. 
Sardjito General Hospital, Yogyakarta and 
Tropical Infectious Disease Policlinic at Dr. 
Kariadi General Hospital, Semarang. For the 
purpose of our study, the inclusion criteria 
were designed for recipients of antiretroviral 
therapy who understood and agreed to 
be involved in the research by signing an 
informed consent form. The exclusion criteria 
were designated as a CD4 T cell count <100 
cells/mm3 and patients who refused to undergo 
ART. 
HIV-1 infection was diagnosed on the 
basis of positive results from 2 HIV rapid test 
diagnostics and HIV antibody ELISA assays. 
Clinical classification of the infected HIV 
patients was based on the National Guidelines 
for the Clinical Management of HIV Infection 
and Antiretroviral Therapy In Adults.7 This 
study was conducted in accordance with the 
Declaration of Helsinki and was approved 
by the Health Research Ethics Committee of 
the Faculty of Medicine, Universitas Gadjah 
Mada and was granted permission by the 
Director of Dr. Sardjito General Hospital, 
Yogyakarta and Dr. Kariadi General Hospital, 
Semarang. Antiretroviral therapy was defined 
as an antiretroviral therapy consisting of 2 
nucleoside analogues and 1 nonnucleoside 
analogue. There was no strict approach to 
antiretroviral treatment; however, each intern 
administered the appropriate ART regimen 
and changed the drugs according to his or her 
interpretation of the patient’s data and on the 
basis of Indonesian guidelines.
Patient data were collected on 
standardized clinic forms and entered into 
a customized electronic record database. 
Baseline evaluations included the medical 
history, physical examination, WHO clinical 
staging, complete blood counts, CD4 cell 
count, and plasma VL. These same clinical 
and laboratory evaluations were performed 6 
months after ART initiation to determine the 
therapy responses.
Laboratory examinations
T lymphocyte subsets were quantified 
by flow cytometry using a Becton Dickinson 
FACSCalibur. Three milliliters of freshly 
isolated peripheral blood was analyzed 
per patient. Whole blood was stained with 
fluorochrome-conjugated monoclonal anti-
bodies: CD3-FITC, CD4-PE, and CD45-
PerCP for CD4 T cells and CD8-FITC, CD38-
PE, and CD45-PerCP for CD8/38 T cells. The 
gating strategy for CD8/38 T cells is shown in 
FIGURE 1. 
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The HIV-1 RNA levels were measured 
using quantitative RT-PCR, Roche COBAS® 
AmpliPrep/COBAS® TaqMan® HIV-1 
Test, v2.0 (Roche, Branchburg, NJ, limit of 
detection (LOD) 20 copies/mL). Six milliliters 
of fresh EDTA blood were centrifuged at 3000 
rpm for 15 minutes to obtain plasma. Plasma 
was stored in a -80oC freezer until the target 
number of samples was reached. The stored 
plasma was sent to the Dharmais Cancer 
Hospital, Jakarta, for VL examination. 
Statistical analysis
Data were monitored for authenticity and 
accuracy and then were coded, tabulated and 
entered into a computer program. Continuous 
data were presented as the mean ± standard 
deviation (SD) if the data distribution was 
normal or the median (min-max) if the 
data distribution was abnormal; however, 
categorical data were presented as frequencies 
and proportions. Statistical analysis used a 
paired t-test, and Spearman’s correlation test.
RESULTS
The clinical characteristics of the 45 
newly infected HIV patients prior to baseline 
are presented in TABLE 1. Among the 
45 treatment-naïve HIV-infected patients 
contributing to these analyses, 86.7% were 
male, 66.7% were homosexual, and 52.3% 
were at clinical stage 1, and the median age 
was 28 (19 to 51) years old. 
TABLE 1. Baseline characteristics of subjects
FIGURE 1. CD8/38 flowcytometry gating strategy
Variable n %
Age (median±SD) 28 (19- 51)
Sex
Male 39 86.7%
Female 6 13.3%
Risk Factor
Heterosexual 27 61.4%
Homosexual 19 43.2%
Injection 3 6.8%
Clinical Stage
1 25 55.6%
2 15 33.3%
3 4 8.9%
Prior to starting HAART, the mean CD4 
T cell count and percentage were 288 ± 131 
cells/uL and 14.96 ± 5.91%, respectively; 
the median VL was 67,400 (49.675-105.649) 
copies/ml; and the median percent of 
activated CD8+ T cells (CD8/38) was 45.30% 
A B
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(40.99-54.10%). After 6 months of ART, 
both VL and the percent of CD8/38 T cells 
were decreased with an increased CD4 T cell 
count and percentage. There were significant 
differences between pre and post ART in all of 
the immunological and virological parameters 
(FIGURE 2). Six months post ART, the mean 
CD4 T cell count and percentage were 433 ± 
150 cells/ uL and 19.27 ± 5.74 %, respectively, 
and the median VL and percent of CD8/38 
were 25 (0.0-97) copies/mL and 30.11 (27.04-
33.89) %, respectively.
FIGURE 2. Pre and post analysis of imunological and virological 
parameter. 
DISCUSSIONS
Similar to most viral infections, HIV 
infections activate T and B-cells, which 
increase CD38 expression as well as other 
immune activation markers.8 Currently, CD38 
has been studied from a prognostic point of 
view in HIV-1 infections. CD38 expression 
is high in peripheral lymphocytes during a 
primary infection, decreases in the transition to 
the asymptomatic phase, and finally increases 
when the disease develops into AIDS. High 
CD38 expression in peripheral CD8 T-cells is 
correlated with poor prognosis and ultimately 
will decrease once ART is administered.9,10 In 
this study, the CD8/38 percentages declined 6 
months post ART, although its level was higher 
compared with the healthy control group, 
which was 7.49±3.97 (3-19) %. This level of 
activated CD8 T cells was from a Thailand 
study that aimed to determine the reference 
range of the CD8/38 T cell percentages in the 
Thai and South East Asian population.10,11 The 
A B
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persistently high levels of activated immune 
cells may have resulted from ongoing virus 
replication, despite the lower levels. In 
addition, co-infection from other viruses, 
such as cytomegalovirus and Epstein-Barr 
virus, are a consequence of mucosal immune 
dysfunction due to decreased CD4 T-cells 
in the acute phase and the loss of intestinal 
barriers that may translocate bacteria to 
systemic circulation.12
The results from this study align with 
Maartens et al.11 after initiating ART, the 
VL levels decreased below the equipment’s 
minimum limit of detection in almost all of the 
patients during the 3 months of ART.11 These 
results support the antigen stimulation theory. 
Human immunodeficiency virus antigens 
were dominant in causing immune activation 
during HIV infection. The declining CD8/38 
T cell percentages 6 months post ART was 
positively correlated with declining VLs 
(r=0.33; p=0.0256; r2=0.109) and (FIGURE 
3). This correlation was weak and showed 
that only 11% proportion of declining VL 
was could be explained by the declining 
CD8/38 percentage. On the contrary, there 
was no significant correlation (r= 0.15, p= 
0.32) between declining VL and CD4 T cell 
recovery after 6 months of ART.
FIGURE 3.  Correlation between the declining of CD8/38 T cell 
percentages and viral load
CD38 expression in CD8 T-cells is a 
marker for activated lymphocytes and can 
predict the progression of the disease.2 Up 
regulation of CD38 in CD8 T-cells reflects 
a dynamic interaction between HIV and 
immune responses.13. In this study, we found 
a weak but significant correlation between 
declining CD8/38 T cells and VL 6 months 
post ART. The CD8/38 percentage accounted 
for only 11% of variance in VL which was 
low. Therefore, although there was a parallel 
decline of CD8/38 cell percentage and VL in 
response to ART, the relationship (correlation) 
has limited value for prediction and not 
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adequately serve as a surrogate marker for 
VL testing. Our results were consisted with 
Steel et al, 2008 that showed poor specificity 
of elevated T cell activation to detect viremia. 
These result suggest that factors unrelated 
to viral replication may play a role in CD38 
expression on CD8 T cells.14
The percentage of CD8/38 T cell might 
be used to determine which patients are at 
risk of having viraemia after treatment and 
should be used to complement CD4 T cell 
counts, the only laboratory examination for 
monitoring ART in developing countries. 
The immunological criteria cannot be used 
to predict virological failure, cannot identify 
almost half of the patients with treatment 
failure and incorrectly identified almost half of 
the patients with immunological failure with 
suppressed VL level. Due to this limitation, 
only monitoring ART by CD4 T cell counts 
will cause drug resistant accumulation and 
unnecessary drug switches. This will increase 
the costs of the national HIV program.4,15 The 
discordant results between virological and 
immunological responses were influenced by 
age, CD4 T cells and VL levels pre ART, ART 
regiments, and co-infection.16,17
CD38 expression in CD8 T-cells differs 
in populations with genetic variations. 
Expression levels may be influenced by 
genetics and the environment; therefore, close 
matching is needed with the control group 
for the same population to determine the 
normal value. This study limitations included 
having no healthy control group, imbalanced 
HIV stages patient proportion and a short 
monitoring period for ART responses.
CONCLUSIONS
We found a significant but weak correlation 
between declining CD8/38 T cell percentages 
and VL 6 months post ART in patients with 
HIV. Despite the parallel decline of both 
CD8/38 percentage and VL, the CD8/38 
percentage had limited value for prediction of 
virological response to ART. CD8/38 T cell 
percentages might be used serially for ART 
monitoring as a complementary laboratory 
examination to CD4 T cell count in the area 
at which VL testing is limited and expensive.
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